UK Meningococcal Vaccines Market Size & Outlook, 2021-2030
UK meningococcal vaccines market, 2018-2030 (US$M)
Related Markets
UK meningococcal vaccines market highlights
- The UK meningococcal vaccines market generated a revenue of USD 155.5 million in 2021 and is expected to reach USD 258.4 million by 2030.
- The UK market is expected to grow at a CAGR of 5.8% from 2022 to 2030.
- In terms of segment, bivalent was the largest revenue generating type in 2021.
- Quadrivalent is the most lucrative type segment registering the fastest growth during the forecast period.
Meningococcal vaccines market data book summary
| Market revenue in 2021 | USD 155.5 million |
| Market revenue in 2030 | USD 258.4 million |
| Growth rate | 5.8% (CAGR from 2021 to 2030) |
| Largest segment | Bivalent |
| Fastest growing segment | Quadrivalent |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bivalent, Quadrivalent |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, UK accounted for 5.4% of the global meningococcal vaccines market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK meningococcal vaccines market is projected to lead the regional market in terms of revenue in 2030.
- Russia is the fastest growing regional market in Europe and is projected to reach USD 27.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK meningococcal vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.
Bivalent was the largest segment with a revenue share of 68.68% in 2021. Horizon Databook has segmented the UK meningococcal vaccines market based on bivalent, quadrivalent covering the revenue growth of each sub-segment from 2018 to 2030.
The meningococcal vaccines market in the UK is one of the lucrative markets in the region. High vaccine uptake against meningitis diseases, better immunization program, and increased R&D activities in the country are expected to drive market growth over the forecast period. In 2015, the UK was the first country to introduce a routine infant 4CMenB immunization program in the country.
Research studies are being performed to evaluate the effectiveness of approved meningococcal vaccine on the incidence of meningitis. For instance, a research study was published in January 2020 that evaluated the effectiveness of 4CMenB/Bexsero on meningococcal group B disease in the UK.
It was found that Bexsero showed positive effects against the disease in children, and protection after 3 doses of the vaccine was effective for a minimum of 2 years. Such studies are estimated to provide data for organizations that conduct immunization programs, which will increase the adoption of vaccine, thereby accelerating market growth.
Reasons to subscribe to UK meningococcal vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK meningococcal vaccines market databook
-
Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK meningococcal vaccines market , including forecasts for subscribers. This country databook contains high-level insights into UK meningococcal vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK meningococcal vaccines market size, by type, 2018-2030 (US$M)
UK Meningococcal Vaccines Market Outlook Share, 2021 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
